CDTX
NASDAQCidara Therapeutics Inc.
Price$221.40+122.95 (+124.89%)
2025-10-022026-01-06
News · 26 weeks730%
2025-11-022026-04-26
Mix090d
No activity.
Latest news
25 items- SECSEC Form 15-12G filed by Cidara Therapeutics Inc.15-12G - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form EFFECT filed by Cidara Therapeutics Inc.EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
- INSIDERDirector Ra Capital Management, L.P. exercised 1,286,786 shares at a strike of $0.00 and returned $1,030,486,444 worth of shares to the company (4,652,309 units at $221.50) (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Cidara Therapeutics Inc.SCHEDULE 13D/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
- INSIDERSEC Form 4 filed by Director Resnick Joshua4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERSEC Form 4 filed by Director Spencer Ryan4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERSEC Form 4 filed by Director Merson James4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERSEC Form 4 filed by Director Canale-Theakston Carin4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERDirector Bassler Bonnie L returned $3,322 worth of shares to the company (15 units at $221.50), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERDirector Mineo Chrysa returned $735,380 worth of shares to the company (3,320 units at $221.50), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERSEC Form 4 filed by Director Schroeder Theodore R4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERDirector Burgess Daniel D returned $33,225 worth of shares to the company (150 units at $221.50) (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERPresident & CEO Stein Jeffrey returned $16,754,260 worth of shares to the company (75,640 units at $221.50), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERChief Financial Officer Karbe Frank returned $1,667,009 worth of shares to the company (50,651 units at $32.91), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERCOO & CLO Ward Shane returned $5,555,884 worth of shares to the company (25,083 units at $221.50), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERChief Medical Officer Davarpanah Nicole Negar returned $2,780,490 worth of shares to the company (20,886 units at $133.13), closing all direct ownership in the company (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- INSIDERPresident & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
- SECSEC Form S-8 POS filed by Cidara Therapeutics Inc.S-8 POS - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form S-8 POS filed by Cidara Therapeutics Inc.S-8 POS - Cidara Therapeutics, Inc. (0001610618) (Filer)
- SECSEC Form S-8 POS filed by Cidara Therapeutics Inc.S-8 POS - Cidara Therapeutics, Inc. (0001610618) (Filer)
CDTX FAQ
7 questionsWhat does Cidara Therapeutics Inc. do?
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for...Where does CDTX stock trade?
Cidara Therapeutics Inc. (CDTX) is listed on NASDAQ.What sector and industry is CDTX in?
Cidara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cidara Therapeutics Inc. go public?
Cidara Therapeutics Inc. (CDTX) completed its IPO in 2015.What are analysts saying about CDTX?
Cidara Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight on 2025-11-17. Recent price targets range from $4100.00 to $4600.00.What companies are similar to CDTX?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), FATE (Fate Therapeutics Inc.), SCYX (SCYNEXIS Inc.), ONTX (Onconova Therapeutics Inc.). Compare CDTX side-by-side with any of them on Quantisnow.How can I track CDTX on Quantisnow?
Quantisnow aggregates Cidara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDTX to receive live email and push alerts on every new disclosure.